Brian Wong, MD
Ophthalmic Plastic and Reconstructive Surgery · Galveston, TXNPI 1417017104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Alcon at 27.7% of the total. 2025 is the largest year on record at $1,566, 4.4 times the $356 reported in 2019.
Across 75 payments — averaging $71.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Carl Zeiss Meditec USA, Inc.$732
- Sight Sciences, Inc.$724
- AbbVie$686
- Bausch & Lomb Americas Inc.$299
- Glaukos Corporation$257
- plus $1K from 11 others
What the payments were for
- Food & beverage$5,396100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $1,496 |
| Carl Zeiss Meditec USA, Inc. | 12 | $732 |
| Sight Sciences, Inc. | 12 | $724 |
| AbbVie | 7 | $686 |
| Bausch & Lomb Americas Inc. | 5 | $299 |
| Glaukos Corporation | 3 | $257 |
| Regeneron Healthcare Solutions, Inc. | 2 | $221 |
| Tarsus Pharmaceuticals, Inc. | 3 | $210 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $173 |
| Amgen | 1 | $125 |
| Carl Zeiss Meditec, Inc. | 2 | $100 |
| Biotissue Holdings Inc. | 1 | $99 |
| Sirtex Medical Inc | 1 | $90 |
| Genentech USA, Inc. | 1 | $86 |
| Argenx US, Inc. | 1 | $42 |
| Medtronic | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$534
- OMNI(R) SURGICAL SYSTEM (US)$480
- XEN GLAUCOMA TREATMENT SYSTEM$267
- SION SURGICAL INSTRUMENT$243
- iStent inject Trabecular Micro-Bypass Stent System$204
- TEPEZZA$125
- CIRRUS HD-OCT$124
- EYLEA HD$122
- AcrySof IQ PanOptix$120
- Humira$120
- AcrySof IQ PanOptix UV IOL$119
- DURYSTA$107
- iStent Trabecular Micro-Bypass Stent System$101
How this compares
$5,396 in reported general payments places this provider in the 80th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.
See all ophthalmic plastic and reconstructive surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 27 | $28,586 |
| Cyclosporine | 28 | $20,716 |
| Restasis MultidoseCyclosporine | 15 | $9,524 |
| Timolol Maleate | 68 | $4,222 |
| Latanoprost | 338 | $3,491 |
| Prednisolone Acetate | 79 | $2,154 |
| Doxycycline Hyclate | 51 | $1,654 |
| MoxifloxacinMoxifloxacin Hcl | 61 | $1,284 |
| Doxycycline Monohydrate | 17 | $1,227 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 44 | $1,111 |
| Ketorolac Tromethamine | 59 | $996 |
| ErythromycinErythromycin Base | 78 | $738 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 61 | $629 |
| Brimonidine Tartrate | 35 | $473 |
| Dorzolamide Hcl | 13 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $686 | $38,11042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.
Other ophthalmic plastic and reconstructive surgery in Galveston
- Vikram DurairajAustin$379K
- David GayDripping Springs$93K
- Richard AllenAustin$32K
- Timothy McCulleyHouston$12K
- Tanya KhanAustin$10K
- Wesley BrundridgeFort Sam Houston$7K
- David HolckSan Antonio$7K
- Irina BelinskyAustin$5K
- Brett DaviesJbsa Lackland$5K
- Margaret PfeifferDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.